These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32452543)

  • 21. Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience.
    Öngören S; Salihoğlu A; Apaydın T; Sadri S; Eşkazan AE; Ar MC; Elverdi T; Başlar Z; Aydın Y; Soysal T
    Balkan Med J; 2018 Nov; 35(6):417-421. PubMed ID: 29966997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
    Lara PN; Coe TL; Zhou H; Fernando L; Holland PV; Wun T
    Am J Med; 1999 Dec; 107(6):573-9. PubMed ID: 10625026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the risk of refractory disease in iTTP.
    Makar RS; Bendapudi PK
    Br J Haematol; 2020 Oct; 191(2):143-144. PubMed ID: 32656761
    [No Abstract]   [Full Text] [Related]  

  • 24. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom.
    Holmes S; Podger L; Bottomley C; Rzepa E; Bailey KMA; Chandler F
    Hematology; 2021 Dec; 26(1):465-472. PubMed ID: 34238132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.
    Patriquin CJ; Thomas MR; Dutt T; McGuckin S; Blombery PA; Cranfield T; Westwood JP; Scully M
    Br J Haematol; 2016 Jun; 173(5):779-85. PubMed ID: 27009919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab.
    Abou-Ismail MY; Arafah Y; Fu P; Cao S; Schmaier AH; Nayak L
    Front Med (Lausanne); 2020; 7():588526. PubMed ID: 33195351
    [No Abstract]   [Full Text] [Related]  

  • 27. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
    Lu R; Sui J; Zheng XL
    Blood Adv; 2020 Nov; 4(21):5378-5388. PubMed ID: 33141886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.
    Falter T; Herold S; Weyer-Elberich V; Scheiner C; Schmitt V; von Auer C; Messmer X; Wild P; Lackner KJ; Lämmle B; Scharrer I
    Thromb Haemost; 2018 Oct; 118(10):1743-1751. PubMed ID: 30235478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura.
    Stubbs MJ; Coppo P; Cheshire C; Veyradier A; Dufek S; Levine AP; Thomas M; Patel V; Connolly JO; Hubank M; Benhamou Y; Galicier L; Poullin P; Kleta R; Gale DP; Stanescu H; Scully MA
    Haematologica; 2022 Mar; 107(3):574-582. PubMed ID: 33596643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura.
    Colling M; Sun L; Upadhyay V; Ryu J; Li A; Uhl L; Kaufman RM; Stowell CP; Dzik WH; Makar RS; Bendapudi PK
    Transfusion; 2020 Apr; 60(4):841-846. PubMed ID: 32080877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians.
    Mancini I; Giacomini E; Pontiggia S; Artoni A; Ferrari B; Pappalardo E; Gualtierotti R; Trisolini SM; Capria S; Facchini L; Codeluppi K; Rinaldi E; Pastore D; Campus S; Caria C; Caddori A; Nicolosi D; Giuffrida G; Agostini V; Roncarati U; Mannarella C; Fragasso A; Podda GM; Birocchi S; Cerbone AM; Tufano A; Menna G; Pizzuti M; Ronchi M; De Fanti A; Amarri S; Defina M; Bocchia M; Cerù S; Gattillo S; Rosendaal FR; Peyvandi F
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33096882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.
    Brodsky MA; Sukumar S; Selvakumar S; Yanek L; Hussain S; Mazepa MA; Braunstein EM; Moliterno AR; Kickler TS; Brodsky RA; Cataland SR; Chaturvedi S
    Am J Hematol; 2021 Dec; 96(12):1587-1594. PubMed ID: 34460124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.
    Clark WF; Rock G; Barth D; Arnold DM; Webert KE; Yenson PR; Kelton JG; Li L; Foley SR;
    Br J Haematol; 2015 Jul; 170(2):208-17. PubMed ID: 25855259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study.
    Huang SS; Pavenski K; Lee TY; Jurkiewicz MT; Bharatha A; Thiessen JD; St Lawrence K; Théberge J; Mandzia J; Barth D; Licht C; Patriquin CJ
    Blood Adv; 2021 Oct; 5(20):4211-4218. PubMed ID: 34521110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura.
    Joffre J; Raia L; Urbina T; Bonny V; Gabarre P; Missri L; Baudel JL; Coppo P; Guidet B; Maury E; Ait-Oufella H
    Crit Care; 2023 Mar; 27(1):116. PubMed ID: 36944989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
    Prevel R; Roubaud-Baudron C; Gourlain S; Jamme M; Peres K; Benhamou Y; Galicier L; Azoulay E; Poullin P; Provôt F; Maury E; Presne C; Hamidou M; Saheb S; Wynckel A; Servais A; Girault S; Delmas Y; Chatelet V; Augusto JF; Mousson C; Perez P; Halimi JM; Kanouni T; Lautrette A; Charvet-Rumpler A; Deligny C; Chauveau D; Veyradier A; Coppo P
    Blood; 2019 Dec; 134(24):2209-2217. PubMed ID: 31530564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion medicine illustrated. Massive hemolysis due to thrombotic thrombocytopenic purpura in a patient with AIDS.
    Adamski J; Marques MB
    Transfusion; 2012 Jul; 52(7):1408-9. PubMed ID: 22780894
    [No Abstract]   [Full Text] [Related]  

  • 39. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.
    Mazepa MA; Masias C; Chaturvedi S
    Blood; 2019 Aug; 134(5):415-420. PubMed ID: 31217190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.